(Reuters) – The torrid pace of deals in the pharmaceutical and biotechnology sectors through 2013 is not expected to let up this year, thanks to new technologies to address unmet medical needs.
Between 2011 and 2016, patents in developed markets will expire on brand-name drugs that…
Analysis: Replay of energetic deal-making seen for drugmakers in 2014
No comments:
Post a Comment